Clinical Trial Update: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of a 6-week Ledipasvir/Sofosbuvir regimen in adults with acute HCV genotype 1 or 4 and HIV co-infection; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatitis Infection with HIV Co-infection

Drugs mentioned

• Ledipasvir/Sofosbuvir (LDV/SOF) fixed-dose combination (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Infection With HIV Co-Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-02-28